Tonix Pharmaceuticals Announces Potential Impact Of The U.S. National Academies New Definition Of Long COVID On The Size Of The Fibromyalgia Market For Tonmya
Portfolio Pulse from Benzinga Newsdesk
Tonix Pharmaceuticals announced that the new definition of Long COVID by the U.S. National Academies could expand the market for its fibromyalgia treatment, Tonmya. This could increase the addressable market size for Tonmya, which is currently under development with a target NDA submission in the second half of 2024 and potential FDA approval in 2025.
July 31, 2024 | 12:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tonix Pharmaceuticals' potential market for its fibromyalgia treatment, Tonmya, could expand due to the new definition of Long COVID by the U.S. National Academies. This could positively impact the company's market size and future revenues.
The new definition of Long COVID by the U.S. National Academies could increase the number of patients diagnosed with fibromyalgia, thereby expanding the addressable market for Tonmya. This is likely to positively impact Tonix Pharmaceuticals' future revenues and market size.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100